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Abstract
Background: Single nucleotide polymorphisms (SNPs) in genes encoding the components involved in the hypothalamic
pathway may influence weight gain and dietary factors may modify their effects.
Aim: We conducted a case-cohort study to investigate the associations of SNPs in candidate genes with weight change
during an average of 6.8 years of follow-up and to examine the potential effect modification by glycemic index (GI) and
protein intake.
Methods and Findings: Participants, aged 20–60 years at baseline, came from five European countries. Cases (‘weight
gainers’) were selected from the total eligible cohort (n = 50,293) as those with the greatest unexplained annual weight gain
(n = 5,584). A random subcohort (n = 6,566) was drawn with the intention to obtain an equal number of cases and noncases
(n = 5,507). We genotyped 134 SNPs that captured all common genetic variation across the 15 candidate genes; 123 met the
quality control criteria. Each SNP was tested for association with the risk of being a ‘weight gainer’ (logistic regression
models) in the case-noncase data and with weight gain (linear regression models) in the random subcohort data. After
accounting for multiple testing, none of the SNPs was significantly associated with weight change. Furthermore, we
observed no significant effect modification by dietary factors, except for SNP rs7180849 in the neuromedin b gene (NMB).
Carriers of the minor allele had a more pronounced weight gain at a higher GI (P= 261027).
Conclusions: We found no evidence of association between SNPs in the studied hypothalamic genes with weight change.
The interaction between GI and NMB SNP rs7180849 needs further confirmation.
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Introduction
The hypothalamic pathway plays a critical role in the
development of obesity through regulating appetite and satiety,
food intake, and thus energy balance [1]. The hypothalamus
integrates gastrointestinal signals such as cholecystokinin (CCK)
and ghrelin, adiposity signals such as leptin, and hypothalamic
signals such as alpa-melanocyte-stimulating hormone (a-MSH)
and its precursor pro-opiomelanocortin (POMC) and neuropep-
tide Y (NPY) [1,2]. Most of the genes encoding these signals have
been proposed as obesity susceptibility genes [3,4], although
findings tend to be inconsistent [3]. For instance, common
polymorphisms in the melanocortin-4 receptor gene (MC4R) have
been associated with human obesity in two candidate gene meta-
analyses [5,6]. Moreover, several common variants near hypotha-
lamic genes such as MC4R and POMC have been identified
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associated with body mass index (BMI) in a recent genome-wide
association study [7]. So far, most candidate genes studies have
been small and often insufficiently powered to identify the small
effects expected. Furthermore, most studies have focused on
concurrent BMI or obesity, whereas only few have aimed at
identifying associations with weight change [8].
In spite of the evidence for a substantial heritable component to
obesity [9], there is no doubt that the recent obesity epidemic is
due to major changes in our living environment, possibly mediated
through an altered lifestyle. During the past decades, many dietary
factors have been investigated for their potential impacts on weight
change or obesity, such as protein intake and dietary glycemic
index (GI) [10,11]. Most, but not all, studies suggest that diets high
in protein and low in GI are beneficial for obesity prevention and
weight control [10,11]. It has been suggested that these diets
enhance satiety, leading to a decreased energy intake, thus prevent
weight gain and promote weight loss [10,11].
The aims of the current case-cohort study were to investigate
whether single nucleotide polymorphisms (SNP) within or near
genes involved in the hypothalamic pathway are associated with
weight gain and to examine whether protein intake and dietary GI
modify their effects. The results will be of relevance for both
understanding the etiology of weight gain and for tailoring dietary
prevention interventions on obesity.
Methods
Ethics statement
EPIC study has been approved by local review board of all
participating institutions, namely the Florence Local Health
Authority Ethical Committee (Italy), the Ethics Committee of
the Norwich District Health Authority (UK), the Medical Ethics
Committee of TNO (Netherlands Organisation for Applied
Scientific Research) (the Netherlands), the Ethics Committee of
the Medical Association of the State of Brandenburg (Germany),
and the Danish National Committee on Biomedical Research
Ethics (Denmark). Written informed consent has been obtained
from all participants before joining EPIC study.
Participants
Participants came from cohorts established in eight regions
within five European countries (Italy, UK, the Netherlands,
Germany, Denmark) participating in the European Prospective
Investigation into Cancer and Nutrition (EPIC) study [12]. The
cohorts were those in the EPIC that had a follow-up program
including reassessment of anthropometry completed. Individuals
were eligible if the following inclusion criteria were met:
younger than 60 years of age at baseline and younger than
65 years at follow-up, blood sample available, had baseline
information on diet, weight and height and follow-up informa-
tion on weight, stable smoking habits, no cancer, cardiovascular
diseases (CVD), and diabetes, and an annual weight change not
more than 5 kg/year. Of the 146,543 participants who took
part in the baseline examination during 1992–1998, a total of
50,293 men and women were eligible to participate in our
study. Cases were defined as those individuals who had
experienced the greatest degree of unexplained annual weight
gain during follow-up (with an average duration of 6.8 years).
They were identified by using the residuals from a regression
model of annual weight change on baseline values of age,
weight and height, smoking status (current/former/never
smokers), and follow-up time. Regression models were run
separately for each country and stratified by gender. For each of
the five countries, except Italy, we randomly selected 600 male
and 600 female cases. As the Italian cohort consisted of a
general population-based sample and of a women-only sample
(population-based breast cancer screening program), men were
underrepresented (27%). Consistent with the sex-ratio in the
Italian cohort, we selected 300 male and 900 female cases. The
subcohort sample comprised a random sample of the total
eligible cohort and was drawn in such a way that the total
number of noncases equaled the number of cases (n = 1,200 in
each country). This resulted in some cases also selected for the
random subcohort. Therefore, oversampling of the random
subcohort was performed, except in Denmark where overlap
between cases and subcohort was negligible (n = 79). In total,
11,921 participants were included in the present genetic
association study: 6,000 cases and a subcohort of 7,061
individuals, of which 5,921 were noncases. The flow chart of
participant selection is shown in Figure 1. The demographic,
anthropometric and dietary characteristics of cases, noncases
and random subcohort are presented in Table 1.
Measurements of diet, anthropometrics and smoking
status
Validated country-specific food frequency questionnaires
(FFQs) were used to collect dietary information at baseline [12].
GI and protein intake were assessed using the methods described
earlier [13,14].
Details of the anthropometric measurements have been
described previously [13,14]. In brief, at baseline all participants
were measured for weight and height using standard study
protocols [15]. At follow-up, participants in the UK and one
center in the Netherlands (Doetinchem) were measured again by
trained technicians, while all other participants measured their
weight at home according to the guidance provided. Therefore
participants from Doetinchem were analyzed separately from
other Dutch participants. As such, we analyzed the data by six
study centers in five countries.
Information on smoking status (never, former, or current
smoker) was collected via self-administered questionnaires at
baseline and at follow-up. Only those who had not changed their
smoking habits during follow-up were included in the analyses.
Selection of candidate genes and tagSNPs
We selected 15 candidate genes based on the available evidence
from literature on their potential roles in body weight regulation
through mechanisms presumed to be implicated in the hypotha-
lamic pathway, either directly or via the interactions with the
dietary GI and protein intake [3]. These genes encode
gastrointestinal signals, adiposity signals and hypothalamic signals
of the hypothalamic pathway, including cholecystokinin (CCK),
CCK A receptor (CCKAR), ghrelin (GHRL), glucagon-like
peptide-1 (GLP-1), peptide YY3-36 (PYY) [16], leptin (LEP),
leptin receptor (LEPR)[17], interleukin-6 (IL-6)[18], neuropeptide
Y (NPY)[19], proopiomelanocortin (POMC)[20], melanocortin 4
receptor (MC4R)[5], nucleobindin 2 (NUCB2)[21], mammalian
target of rapamycin (mTOR) [22], neuromedin b (NMB)[23], and
5-hydroxytryptamine (serotonin) receptor 1A (5-HT1A)[24]. A
figure summarizing the interrelationship between many of the
hypothalamic hormones in relation to their role in the regulation
of food intake can be found in a recent review [1].
We used the International HapMap data for European ancestry
(CEU) (release 20, NCBI Build 35) to select SNPs such that full
coverage of the common genetic variation in the candidate genes
(+/25 kb) was ensured.
The Haploview software V3.3 was used to assess the linkage
disequilibrium (LD) structure between SNPs [25]. Tagger software
SNPs in Hypothalamic Pathway and Weight Change
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was used to select tagSNPs with the ‘pairwise tagging only’ option
and an r2 threshold of 0.8. In total, 134 SNPs were selected using
the pre-requisite criteria (minor allele frequency (MAF) $5% and
Hardy-Weinberg Equilibrium (HWE) P.0.01). A complete list of
the selected SNPs, including the candidate genes, is shown in a
Table S1.
DNA extraction and genotyping
Genomic DNA was extracted from the buffy coats with a salting
out method [26], except for participants from the UK, for whom
whole-genome amplified DNA was used. Genomic and amplified
DNA samples were quality-checked, quantified and normalized to
approximately 100 ng/ml and 2.0 mg before genotyping. High
throughput SNP genotyping was carried out using the IlluminaH
Beadstation Genotyping System at IntegraGen, France.
Genotyping was considered successful if the following quality
control criteria were met within each country: sample call rate
$95%, SNP call rate $95%, and duplicate discordance rate
#3%.
We subjected all SNPs to country-specific HWE genotype
distribution-tests. Significant deviations from equilibrium were
defined as P#0.001 and then lead to exclusion of that particular
SNP-country genotype data. In total, 123 SNPs passed the tests for
at least one country and were successfully genotyped for 11,091
participants. The case group included 5,584 participants and the
subcohort included 6,566 participants of whom 5,507 were
noncases.
Statistical methods
Power calculations were performed using QUANTO software,
Version 1.2.4 (May 2009) [27]. The minimum detectable effects,
at 80% power, ranged from OR (odds ratio) 1.44 for a SNP with a
MAF of 5% to OR 1.08 for a SNP with a MAF 50% in the case-
noncase analyses and from regression coefficient (b) 88 g/year to b
40 g/year in random subcohort analyses.
Each SNP was coded 0, 1 and 2 according to the number of
minor alleles an individual carries.
First, the association between each SNP and BMI at baseline
was tested using linear regression, assuming an additive effect of
the minor allele. Analyses were adjusted for age, gender, height
and smoking status.
Figure 1. Flow diagram of participant selection.
doi:10.1371/journal.pone.0017436.g001
Table 1. Characteristics of participants of cases, noncases and
subcohort.
Cases Noncases P values1 Subcohort
(n =5,584) (n=5,507) (n =6,566)
Age, yrs 47.667.5 48.067.3 0.003 47.967.3
Gender, %men 45 45 matched 46
Overweight, % 43 39 ,0.0001 39
Obesity, % 17 9 ,0.0001 10
Baseline weight, kg 76.3614.3 72.6613.4 ,0.0001 73.2613.6
Baseline BMI, kg/m2 26.464.2 25.263.6 ,0.0001 25.463.7
Annual weight
change, g/yr
1,4286684 306622 ,0.0001 2456801
BMI at follow-up,
kg/m2
29.464.4 25.363.5 ,0.0001 25.963.9
Follow-up time, yrs 6.862.5 6.862.5 0.08 6.962.5
Glycemic index (GI) 56.664.3 56.564.1 0.4 56.564.1
Protein intake, g 89.9629.4 89.2627.1 0.2 89.6628.2
Values presented are mean 6 standard deviation or percentage (%) as
indicated.
1P values for the difference between cases and noncases, tested by student
t-test (for continuous variables) or Cochran-Armitage trend test (categorical
variables).
doi:10.1371/journal.pone.0017436.t001
SNPs in Hypothalamic Pathway and Weight Change
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e17436
Subsequently, we tested for association with weight gain over
time. The association of each SNP with the risk of being a ‘weight
gainer’ (case-noncase analysis) was examined using a logistic
regression assuming an additive effect of the minor allele. The
association between each SNP and annual weight change (g/year)
(random subcohort analysis) was tested using linear regression and
assuming an additive effect of the minor allele.
Case-noncase analyses of main effects were not adjusted,
whereas random subcohort analyses were adjusted for variables
that had been included in the case-status defining model (i.e.
baseline values of age, weight and height, gender, smoking status,
and follow-up time) to reduce the residual variation.
SNP-dietary factor interaction analyses were performed by
including the corresponding interaction term as well as the
complementary dietary main effect term in the model.
All association analyses were first conducted for each study
center separately and then summary statistics were meta-analyzed.
We used random effects to account for the possible heterogeneity
across study centers. Heterogeneity across study centers was tested
using the Cochran Q-test [28].
Multiple comparisons were corrected for using the Bonferroni
method. Number of tests corrected for was chosen as the number
of SNPs studied (n= 123) and P,461024 (0.05/123) was
considered significant.
All association analyses were conducted using STATA 9.2 for
Windows (StataCorp LP, Texas, USA). The descriptive analyses
were performed with SAS 9.1 for Windows (SAS Institute, Cary,
NC).
Results
None of the associations between the 123 SNPs and baseline
BMI in the subcohort was significant after accounting for multiple
testing, yet three associations reached nominal significance
(P,0.05) (LEPR SNP rs3790426 b=0.18 kg/m2 per minor allele,
P=0.01; LEP SNP rs2278815 b=20.14 kg/m2 per minor allele,
P=0.03; NUCB2 SNP rs10832763 b=0.16 kg/m2 per minor
allele, P=0.03) (Table S2).
In case-noncase analyses, none of the associations or interac-
tions under investigation were considered significant after the
correction for multiple testing. However, two SNPs showed a
nominally significant association with the risk of being a ‘weight
gainer’ (PYY SNP rs1859223, OR=0.91 per minor allele,
P=0.01; CCK SNP rs11571842, OR=1.06 per minor allele,
P=0.03) (Table S3). The interactions between two SNPs with
protein intake (IL-6 SNP rs12700386 and LEPR SNP rs1887285)
and between nine other SNPs and GI (CCK SNP rs9311317, LEPR
SNP rs1137101, POMC SNP rs6713532, two NMB SNPs,
rs2292462 and rs7180849, and four NPY SNPs, rs16135,
rs16472, rs5574, and rs9785023) reached nominal significance
level (P,0.05) (Table S4).
Again, in the random subcohort analyses, none of the SNP-
weight change associations was significant after multiple testing
correction, in spite of the three nominally significant associations
of LEPR SNP rs10493380 (b=230 g/year per minor allele,
P=0.04), PYY SNP rs1058046 (b=2 28 g/year per minor allele,
P=0.02), and GHRL SNP rs26802 (b=25 g/year per minor
allele, P=0.04) with weight change (Table S5).
None of the SNP-GI and SNP-protein interaction were
found to be significant after multiple testing correction, apart
from the interaction between the NMB rs7180849 SNP and GI
remained significant (b=25 g/year per allele per unit increase
in GI, P=261027). More specifically, the minor allele of the
NMB rs7180849 SNP was associated with a 25 g/y greater
increase in weight for every unit increase in GI. As shown in
Figure 2, from the lowest GI quintile (mean GI <50) to the
highest GI quintile (mean GI <63), the annual weight change
of the participants with the AA genotype increased from
2195 g/year to 526 g/year, while the weight change among
those with GA genotype was much smaller (from 220 g/year
to 344 g/year) and the weight change of those with the GG
genotype hardly differed (from 154 g/year to 161 g/year). In
addition, we also observed two nominally significant (P,0.05)
interactions for two SNPs with protein intake (LEP SNP
rs7788818 and NMB SNP rs7180849) and for eight SNPs with
GI (GHRL SNP rs35683, NUCB2 SNP rs214075, POMC SNP
rs67565427, two NMB SNPs, rs2292462 and rs7180849, and
three LEPR SNPs, rs1137101, rs2025805 and rs9436740)
(Table 2 & Table S6).
No significant heterogeneity was observed for any of the above
mentioned associations (P.0.2 for all).
Discussion
In this large case-cohort study among European adults, we
studied the associations of 123 SNPs in 15 candidate genes
Figure 2. The regression of weight change on glycemic index (GI) by genotypes of SNP rs7180849 near neuromedin b gene gene
(NMB) (n =5,117 - distributed over genotypes as GG=3,549, AG=1,431, and AA=137).
doi:10.1371/journal.pone.0017436.g002
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involved in the hypothalamic pathway with weight change.
Despite the fact that our study has sufficient power to detect
small effects, we did not observe significant associations between
any of the SNPs and weight change or risk of being a ‘weight
gainer’. Furthermore, dietary protein intake and GI did not
modify the association between SNPs and weight change, except
for the NMB rs7180849 that seemed to increase weight gain in
those on a high GI diet.
The selection of genes for our study was based on a hypothesis-
driven candidate gene approach. We selected only those genes that
have a well-defined role in regulating the ‘hypothalamic pathway’,
variants in which are associated with obesity-related traits. Studies
in humans and animals have shown that administration of CCK,
PYY, GLP-1, and NMB could decrease food intake but
administration of ghrelin and NPY leads to obesity
[29,30,31,32]. Variants in or near LEP, POMC, MC4R, and IL-6
genes confer a significant risk to human obesity [33,34,35].
mTOR is an important mediator between the adiposity signal,
leptin, and hypothalamic signals; the inhibition of mTOR
signalling blunts leptin’s anorectic effect [2,22,36]. Serotonin
systems (5-HT1A) could upregulate the expression of NUCB2, a
hypothalamic peptide with anorexigenic effect [21,37], and induce
anorexia [38].
The critical role of food intake regulation and the hypothal-
amus pathway in weight change and obesity has long been
recognized [1,2]. A number of studies observed associations
between genetic variations in this pathway and obesity-related
phenotypes [3]. There is also evidence suggesting that dietary GI
and protein intake affect food intake and weight change through
satiety regulation [10,39,40,41]. Several studies have shown that
these dietary factors could influence the hypothalamic pathway
signaling. High protein diet has been found to decrease
postprandial ghrelin concentrations and increase GLP-1 and
PYY release and also found to reduce gastric emptying through
increased secretion of CCK and GLP-1 [42,43]. In a recent
randomized controlled trial, low GI diet has been associated with
a lower day-long concentration of glucose and insulin, and a
higher level of CCK [44]. However, we are not aware of any
study which has examined whether associations between SNPs of
hypothalamic genes and weight gain are modified by these
dietary factors.
In the present study, we did not observe significant main
effects of any of the SNPs on either weight change or baseline
BMI. Furthermore, no significant effect modification by dietary
protein was observed either. The confidence intervals of the
observed estimates were narrow, reflecting a sound reliability of
our findings (online supplementary tables). In the random
subcohort analyses, we observed a significant interaction
between GI and NMB SNP rs7180849; i.e. each additional
minor allele of rs7180849 was associated with increased weight
gain in those on a high GI diet. Although consistent with our
observations for weight gain as a continuous trait, the
interaction observed in the case-noncase analyses was only
borderline significant after correcting for multiple testing
(P=0.002). We speculate that the apparent weaker interaction
observed in the case-noncase analysis compared to the cohort
analysis could be ascribed to the difference in study design.
More specifically, despite a larger sample size, the case-noncase
design does not necessarily provide more statistical power.
Furthermore, the outcomes examined may represent different
phenotypes; i.e. the case-noncase analysis examines association
with weight gainers at the extremes of the distribution, while the
Table 2. Interactions of SNPs with dietary glycemic index (GI) and protein intake on weight gain in random subcohort analyses
(n = 6,566).
Gene Number of SNPs 1 minor allele61 unit GI 1 minor allele61 gram protein
b (kg/m2) 1 P value2 b (kg/m2) 1 P value2
Lowest Highest Lowest Highest Lowest Highest Lowest Highest
CCK 8 26 4 0.2 0.9 28 10 0.2 1.0
CCKAR 5 22 10 0.3 0.6 28 2 0.2 0.8
GHRL 12 28 8 0.03 1.0 29 10 0.09 1.0
GLP-1 2 28 4 0.2 0.4 23 22 0.7 0.8
5-HT1A 1 24 24 0.3 0.3 25 25 0.3 0.3
IL-6 7 212 7 0.05 0.8 25 12 0.1 0.9
LEP 6 27 5 0.09 0.9 230 11 0.008 0.8
LEPR 35 217 11 0.02 1.0 211 8 0.2 0.9
MC4R 3 0.1 7 0.2 1.0 22 6 0.4 0.9
mTOR 4 26 14 0.2 0.9 213 7 0.3 0.8
NMB 4 26 25 261027 0.9 220 12 0.02 0.9
NPY 8 25 7 0.1 0.8 24 4 0.6 1.0
NUCB2 12 26 9 0.006 0.9 28 12 0.06 1.0
POMC 9 221 12 0.04 0.9 29 11 0.07 1.0
PYY 7 27 5 0.3 1.0 28 0.5 0.09 1.0
SNP: single nucleotide polymorphism.
1Values presented are the overall meta-analyzed regression coefficients. The lowest and highest values are the minimum and maximum b among the SNPs in that
specific gene.
2P values of the meta-analyzed bs. The lowest and highest values are the minimum and maximum P value among the SNPs in that specific gene.
doi:10.1371/journal.pone.0017436.t002
SNPs in Hypothalamic Pathway and Weight Change
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e17436
cohort analysis examine weight change in the general popula-
tion. In additional analyses, we also found that rs7180849
significantly interacted with GI on waist circumference change
(P=1.561025 in random subcohort analyses).
NMB is a decapeptide that belongs to the bombesin-like peptide
family and is widely distributed in the human central nervous
system, pancreas, adrenals, gastrointestinal tract and adipose tissue
[23]. Evidence shows that NMB, when released in the gastrointes-
tinal tract in response to food intake, represents a mediator between
the gut and the brain and serves as a satiation signal to terminate
meals [23]. NMB is also expressed in adipose tissue and can act as
an adiposity signal reflecting nutritional status and regulating food
intake over a longer term [23,45]. Intravenous infusion of NMB has
been shown to reduce meal size and meal duration in rats [32]. The
rs7180849 is located at ,2.7 kb upstream of the NMB (Figure 3)
and is in complete LD (r2 = 1.0, D9=1.0 in CEU Hapmap) with
SNP rs3809508 which is positioned in the intron region of the NMB.
In a recent study among 1,144 European adolescents, the TT
genotype (homozygous minor allele carriers) of the rs3809508 was
associated with a higher risk of obesity and this association was
stronger among those adolescents whose mothers had the lowest
education level [46]. Given the close association between low
education and unhealthy eating habits (i.e. a high GI diet), it might
be possible that the influence of SNP rs3809508 on obesity risk was,
at least partly, modified by dietary GI. In the Quebec Family Study,
a missense mutation p.P73T in the NMB has been associated with
eating behaviors associated with obesity and the amount of body fat
gain during a 6-year follow-up [47]. The silent polymorphism
g.G401A in the NMB has been significantly associated with body
weight in children and adolescents [48]. However, there is no
identified function of either rs7180849 or rs3809508 on NMB
expression or function so far.
The main strengths of the current study include its large scale,
the multi-center and prospective properties and the full capture of
common genetic variation in the candidate genes. A potential
weakness might be the self-reported information on body weight at
follow-up in four out of six study centers [13]. However, using this
data, it has been observed in our previous studies that correction
for underreporting using the available methods did not change the
main findings [13].
To conclude, among this European population from five
countries, none of the 123 SNPs in or near 15 candidate genes
involved in the hypothalamic regulation pathway of food intake
had a significant main effect on the risk of weight gain. With the
exception of NMB SNP, rs7180849, showing a significant
interaction with dietary GI, none of the SNPs showed
interactions with the GI or protein content of the diet in their
associations with weight change and the risk of being a ‘weight
gainer’. This finding suggests that individuals carrying the NMB
minor allele (G allele) are more vulnerable to the deleterious
effects of a high GI diet in terms of weight gain. Thus, lowering
dietary GI seems more important for the minor-allele carriers in
weight regulation. However, further studies are needed to verify
this finding.
Figure 3. Linkage disequilibrium (LD) plot of the neuromedin b gene (NMB) 1.
doi:10.1371/journal.pone.0017436.g003
SNPs in Hypothalamic Pathway and Weight Change
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e17436
Supporting Information
Table S1 List of the genes (n=15) and single nucleotide
polymorphisms (SNPs) (n=134) selected for genotyping.
(DOC)
Table S2 Cross-sectional associations of 123 single
nucleotide polymorphisms (SNPs) from the hypotha-
lamic pathway with baseline body mass index (BMI,
kg/m2).
(DOC)
Table S3 Association of 123 single nucleotide polymor-
phisms (SNPs) from the hypothalamic pathway with the
risk of being a ‘weight gainer’ in case - noncase analysis
(n=11,091).
(DOC)
Table S4 Interaction of 123 single nucleotide polymor-
phisms (SNPs) from the hypothalamic pathway with
glycemic index (GI) and protein intake on the risk of
being a ‘weight gainer’ in case - noncase analysis
(n=11,091).
(DOC)
Table S5 Association of 123 single nucleotide polymor-
phisms (SNPs) from the hypothalamic pathway with
weight gain (g/year) in random subcohort analysis
(n= 6,566).
(DOC)
Table S6 Interactions of 123 single nucleotide polymor-
phisms (SNPs) from the hypothalamic pathway with
glycemic index (GI) and protein intake on weight gain
(g/year) in random subcohort analysis (n= 6,566).
(DOC)
Acknowledgments
We thank the European Prospective Investigation on Cancer and Nutrition
(The EPIC project: http://epic.iarc.fr/) for allowing access to the data.
Author Contributions
Conceived and designed the experiments: TIAS NJW RJFL. Performed
the experiments: HD KSV. Analyzed the data: LA¨ CH. Contributed
reagents/materials/analysis tools: DLvdA NJW AT KO HB DP TIAS
WHMS EJMF RJFL. Wrote the paper: HD KSV. RDH MUJ KM GM.
Contributed to the SNP selection; read and approved the final version of
the manuscript: NB-N.
References
1. Lenard NR, Berthoud HR (2008) Central and peripheral regulation of food
intake and physical activity: pathways and genes. Obesity (Silver Spring)
16(Suppl 3): S11–22.
2. Woods SC, Seeley RJ, Cota D (2008) Regulation of food intake through
hypothalamic signaling networks involving mTOR. Annu Rev Nutr 28:
295–311.
3. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, et al.
(2006) The human obesity gene map: the 2005 update. Obesity (Silver Spring)
14: 529–644.
4. Yang W, Kelly T, He J (2007) Genetic epidemiology of obesity. Epidemiol Rev
29: 49–61.
5. Young EH, Wareham NJ, Farooqi S, Hinney A, Hebebrand J, et al. (2007) The
V103I polymorphism of the MC4R gene and obesity: population based studies
and meta-analysis of 29 563 individuals. Int J Obes (Lond) 31: 1437–1441.
6. Stutzmann F, Vatin V, Cauchi S, Morandi A, Jouret B, et al. (2007) Non-
synonymous polymorphisms in melanocortin-4 receptor protect against obesity:
the two facets of a Janus obesity gene. Hum Mol Genet 16: 1837–1844.
7. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, et al.
Association analyses of 249,796 individuals reveal 18 new loci associated with
body mass index. Nat Genet 42: 937–948.
8. Qi L, Kraft P, Hunter DJ, Hu FB (2008) The common obesity variant near
MC4R gene is associated with higher intakes of total energy and dietary fat,
weight change and diabetes risk in women. Hum Mol Genet 17: 3502–3508.
9. Maes HH, Neale MC, Eaves LJ (1997) Genetic and environmental factors in
relative body weight and human adiposity. Behav Genet 27: 325–351.
10. Du H, van der A DL, Feskens EJ (2006) Dietary glycaemic index: a review of the
physiological mechanisms and observed health impacts. Acta Cardiol 61:
383–397.
11. St Jeor ST, Howard BV, Prewitt TE, Bovee V, Bazzarre T, et al. (2001) Dietary
protein and weight reduction: a statement for healthcare professionals from the
Nutrition Committee of the Council on Nutrition, Physical Activity, and
Metabolism of the American Heart Association. Circulation 104: 1869–1874.
12. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, et al. (2002) European
Prospective Investigation into Cancer and Nutrition (EPIC): study populations
and data collection. Public Health Nutr 5: 1113–1124.
13. Du H, van der A DL, van Bakel MM, Slimani N, Forouhi NG, et al. (2009)
Dietary glycaemic index, glycaemic load and subsequent changes of weight and
waist circumference in European men and women. Int J Obes (Lond) 33:
1280–1288.
14. Halkjær J, Olsen A, Overvad K, Jakobesen MU, Boeing H, et al. (2010) Intake of
total, animal and plant protein and subsequent changes in weight or waist
circumference in European men and women: the Diogenes project. Int J Obes
(Lond) In press.
15. Rinaldi S, Key TJ, Peeters PH, Lahmann PH, Lukanova A, et al. (2006)
Anthropometric measures, endogenous sex steroids and breast cancer risk in
postmenopausal women: a study within the EPIC cohort. Int J Cancer 118:
2832–2839.
16. Huda MS, Wilding JP, Pinkney JH (2006) Gut peptides and the regulation of
appetite. Obes Rev 7: 163–182.
17. Friedman JM (1998) Leptin, leptin receptors, and the control of body weight.
Nutr Rev 56: s38–46; discussion s54-75.
18. Andersson N, Strandberg L, Nilsson S, Adamovic S, Karlsson MK, et al. (2010)
A variant near the interleukin-6 gene is associated with fat mass in Caucasian
men. Int J Obes (Lond) 34: 1011–1019.
19. Beck B (2006) Neuropeptide Y in normal eating and in genetic and dietary-
induced obesity. Philos Trans R Soc Lond B Biol Sci 361: 1159–1185.
20. Coll AP, Loraine Tung YC (2009) Pro-opiomelanocortin (POMC)-derived
peptides and the regulation of energy homeostasis. Mol Cell Endocrinol 300:
147–151.
21. Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, et al. (2010)
Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-
specific adipokine with increased levels in obesity. Endocrinology 151:
3169–3180.
22. Dann SG, Selvaraj A, Thomas G (2007) mTOR Complex1-S6K1 signaling: at
the crossroads of obesity, diabetes and cancer. Trends Mol Med 13: 252–259.
23. Hoggard N, Bashir S, Cruickshank M, Miller JD, Speakman JR (2007)
Expression of neuromedin B in adipose tissue and its regulation by changes in
energy balance. J Mol Endocrinol 39: 199–210.
24. Fetissov SO, Meguid MM (2010) Serotonin delivery into the ventromedial
nucleus of the hypothalamus affects differently feeding pattern and body weight
in obese and lean Zucker rats. Appetite 54: 346–353.
25. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
26. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for
extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
27. Gauderman WJ, Morrison JM QUANTO 1.1: A computer program for power
and sample size calculations for gene-epidemiology studies (2006) http://hydra.
usc.edu/gxe.
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring
inconsistency in meta-analyses. Bmj 327: 557–560.
29. Swartz TD, Duca FA, Covasa M (2010) Differential feeding behavior and
neuronal responses to CCK in obesity-prone and -resistant rats. Brain Res 1308:
79–86.
30. Small CJ, Bloom SR (2004) Gut hormones as peripheral anti obesity targets.
Curr Drug Targets CNS Neurol Disord 3: 379–388.
31. Williams G, Harrold JA, Cutler DJ (2000) The hypothalamus and the regulation
of energy homeostasis: lifting the lid on a black box. Proc Nutr Soc 59: 385–396.
32. Rushing PA, Gibbs J, Geary N (1996) Brief, meal-contingent infusions of gastrin-
releasing peptide1-27 and neuromedin B-10 inhibit spontaneous feeding in rats.
Physiol Behav 60: 1501–1504.
33. Farooqi S, O’Rahilly S (2006) Genetics of obesity in humans. Endocr Rev 27:
710–718.
34. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, et al. (2008) Common
variants near MC4R are associated with fat mass, weight and risk of obesity. Nat
Genet 40: 768–775.
35. Qi L, Zhang C, van Dam RM, Hu FB (2007) Interleukin-6 genetic variability
and adiposity: associations in two prospective cohorts and systematic review in
26,944 individuals. J Clin Endocrinol Metab 92: 3618–3625.
SNPs in Hypothalamic Pathway and Weight Change
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17436
36. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, et al. (2006)
Hypothalamic mTOR signaling regulates food intake. Science 312: 927–930.
37. Shimizu H, Ohsaki A, Oh IS, Okada S, Mori M (2009) A new anorexigenic
protein, nesfatin-1. Peptides 30: 995–998.
38. Nonogaki K, Ohba Y, Sumii M, Oka Y (2008) Serotonin systems upregulate the
expression of hypothalamic NUCB2 via 5-HT2C receptors and induce anorexia
via a leptin-independent pathway in mice. Biochem Biophys Res Commun 372:
186–190.
39. Bornet FR, Jardy-Gennetier AE, Jacquet N, Stowell J (2007) Glycaemic response
to foods: impact on satiety and long-term weight regulation. Appetite 49:
535–553.
40. Westerterp-Plantenga MS (2003) The significance of protein in food intake and
body weight regulation. Curr Opin Clin Nutr Metab Care 6: 635–638.
41. Halton TL, Hu FB (2004) The effects of high protein diets on thermogenesis,
satiety and weight loss: a critical review. J Am Coll Nutr 23: 373–385.
42. Blom WA, Lluch A, Stafleu A, Vinoy S, Holst JJ, et al. (2006) Effect of a high-
protein breakfast on the postprandial ghrelin response. Am J Clin Nutr 83:
211–220.
43. Veldhorst M, Smeets A, Soenen S, Hochstenbach-Waelen A, Hursel R, et al.
(2008) Protein-induced satiety: effects and mechanisms of different proteins.
Physiol Behav 94: 300–307.
44. Reynolds RC, Stockmann KS, Atkinson FS, Denyer GS, Brand-Miller JC (2009)
Effect of the glycemic index of carbohydrates on day-long (10 h) profiles of
plasma glucose, insulin, cholecystokinin and ghrelin. Eur J Clin Nutr 63:
872–878.
45. Spalova J, Zamrazilova H, Vcelak J, Vankova M, Lukasova P, et al. (2008)
Neuromedin beta: P73T polymorphism in overweight and obese subjects.
Physiol Res 57 Suppl 1: S39–48.
46. Pigeyre M, Bokor S, Romon M, Gottrand F, Gilbert CC, et al. (2010) Influence
of maternal educational level on the association between the rs3809508
neuromedin B gene polymorphism and the risk of obesity in the HELENA study.
Int J Obes (Lond) 34: 478–486.
47. Bouchard L, Drapeau V, Provencher V, Lemieux S, Chagnon Y, et al. (2004)
Neuromedin beta: a strong candidate gene linking eating behaviors and
susceptibility to obesity. Am J Clin Nutr 80: 1478–1486.
48. Oeffner F, Bornholdt D, Ziegler A, Hinney A, Gorg T, et al. (2000)
Significant association between a silent polymorphism in the neuromedin B
gene and body weight in German children and adolescents. Acta Diabetol 37:
93–101.
SNPs in Hypothalamic Pathway and Weight Change
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e17436
